This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Alumis’s 8K filing here.
Alumis Company Profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
- Five stocks we like better than Alumis
- How to Calculate Return on Investment (ROI)
- Rocket Lab is the Right Stock for the Right Time
- 3 Fintech Stocks With Good 2021 Prospects
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Why Invest in 5G? How to Invest in 5G Stocks
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
